Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Tolerability of Sotatercept for Patients with Pulmonary Arterial Hypertension

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Pulmonary Arterial Hypertension (PAH), a condition where the blood pressure in the arteries of the lungs is higher than normal. The study will use a treatment called sotatercept, which is administered as a solution for injection. Sotatercept is being tested to see how safe and tolerable it is for people with PAH when given in doses based on their weight.

The purpose of the study is to evaluate the long-term safety and tolerability of sotatercept. Participants will receive sotatercept through injections under the skin. The study will monitor participants over a period to observe any side effects or adverse events that may occur. The study aims to ensure that sotatercept can be safely used by people with PAH as part of their standard care.

Participants in this study will have completed a previous study involving sotatercept and will not have started treatment with commercially available sotatercept. The study will track the number of participants who experience adverse events and those who discontinue the study due to these events. This information will help determine the safety of sotatercept for long-term use in managing PAH.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the purpose and procedures involved. This study is designed to evaluate the long-term safety and tolerability of sotatercept in individuals with pulmonary arterial hypertension (PAH).

  2. Step 2

    Eligibility confirmation

    Your eligibility will be confirmed based on specific criteria. You must have completed the treatment period of the previous study (MK-7962-024) and not have started treatment with commercially available sotatercept.

  3. Step 3

    Treatment administration

    You will receive sotatercept as a solution for injection. The medication will be administered subcutaneously, which means it will be injected under the skin. The dosage will be determined using a weight-banded approach, ensuring it is appropriate for your body weight.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, you will be monitored for any adverse events, which are any unwanted effects or reactions. Regular follow-up visits will be scheduled to assess your health and the tolerability of the treatment.

  5. Step 5

    Study duration

    The study is expected to continue until September 30, 2027. Your participation will involve regular visits and assessments during this period to ensure your safety and the effectiveness of the treatment.

Who can join the trial?

5 criteria

  • The patient must have completed the treatment period of the study called MK-7962-024 (LIGHTRAY), including Visit 11, without stopping the study treatment.
  • The patient must be able to safely join the new study called MK-7962-031 (LIGHTRAY EXTENSION).
  • The patient must not have started treatment with the commercially available drug called sotatercept.
  • The patient can be of any gender, as both males and females are eligible.
  • The patient must be within the age range specified by the study, which includes both adults and older adults.

Who cannot join the trial?

10 criteria

  • Patients with any other serious medical condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have had a recent heart attack or stroke.
  • Patients with uncontrolled high blood pressure.
  • Patients who have had a major surgery within the last 3 months.
  • Patients with a history of severe allergic reactions to similar medications.
  • Patients who are currently participating in another clinical trial.
  • Patients with severe liver or kidney disease.
  • Patients with a history of drug or alcohol abuse within the last year.
  • Patients who are unable to comply with the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Sotatercept (MK-7962) is a medication being studied for its potential to help people with Pulmonary Arterial Hypertension (PAH). PAH is a condition where the blood pressure in the arteries of the lungs is higher than normal, which can make it hard for the heart to pump blood through the lungs. Sotatercept works by targeting specific pathways in the body that are involved in the development of PAH. The goal of this study is to see if sotatercept is safe and can be tolerated by patients over a long period. It is given to patients based on their weight, which means the amount of medication is adjusted according to how much a person weighs. This study is an open-label extension, meaning that both the researchers and the participants know that they are receiving sotatercept, and it is added to the standard treatments that patients with PAH are already receiving.

What is already known about the treatment

Sotatercept – Sotatercept is administered through an injection, using a weight-banded approach, which means the dose is adjusted based on the patient's weight. It is currently being studied in clinical trials to assess its long-term safety and tolerability for treating Pulmonary Arterial Hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. Sotatercept works by targeting specific proteins in the body to help reduce the abnormal growth of blood vessels in the lungs, which can improve blood flow and reduce pressure. It is classified as a therapeutic agent for PAH, focusing on improving the quality of life for patients with this condition.

Investigated diseases

Pulmonary Arterial Hypertension (PAH) – Pulmonary Arterial Hypertension is a condition characterized by high blood pressure in the arteries that supply the lungs. This disease causes the small arteries in the lungs to become narrowed or blocked, leading to increased resistance to blood flow. As a result, the heart must work harder to pump blood through these arteries. Over time, this increased workload can lead to the enlargement and weakening of the heart. Symptoms often include shortness of breath, fatigue, dizziness, and swelling in the ankles or legs. The progression of the disease can lead to further complications affecting the heart and lungs.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518687-12-00Protocol codeMK-7962-031Estimated enrolment212 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.